Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

计划入组 74 人 · 首次发布于 2016 年 1 月 8 日

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

计划入组 25 人 · 首次发布于 2024 年 12 月 16 日

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

计划入组 17 人 · 首次发布于 2018 年 4 月 27 日

Enzalutamide(Xtandi, Enzalutamide Viatris)

C₂₁H₁₆F₄N₄O₂S · Rx

Abiraterone(Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan, Akeega)

C₂₄H₃₁NO

Apalutamide(Erleada)

<dd class="col-xl-8 col-md-9 col-sm-8">C₂₁H₁₅F₄N₅O₂S</dd> · Rx

PROSTATE LASER CENTER, PLLC

United States

NEW YORK PROSTATE INSTITUTE

United States

Arvinas

United States

AI Biomarker Predicts Survival and Treatment Response in Oligometastatic Prostate Cancer

Ontario Expands Public Coverage of XTANDI for High-Risk Prostate Cancer Patients

JAMP Pharma Group Launches Generic Enzalutamide for Prostate Cancer Treatment in Canada